Comparative Pharmacology
Head-to-head clinical analysis: ADENOCARD versus MULTAQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADENOCARD versus MULTAQ.
ADENOCARD vs MULTAQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adenosine is an endogenous purine nucleoside that acts on A1 and A2 adenosine receptors. It slows conduction through the AV node, interrupts reentry pathways, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT).
Dronedarone is a multichannel blocker that inhibits potassium currents (IKr, IKs, IK-ACh), sodium current (INa), and L-type calcium current (ICaL), and has antiadrenergic properties via noncompetitive blockade of beta-adrenergic receptors.
6 mg IV bolus over 1-2 seconds, followed by 20 mL saline flush; if no conversion to sinus rhythm within 1-2 minutes, give 12 mg IV bolus; may repeat 12 mg once more if needed.
400 mg orally twice daily with morning and evening meals.
None Documented
None Documented
Terminal half-life is less than 10 seconds; clinically, the effect is very transient due to rapid cellular uptake and metabolism.
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) after oral administration, allowing for twice-daily dosing.
Primarily renal excretion of metabolites; adenosine is rapidly metabolized intracellularly to inosine and adenosine monophosphate, with less than 1% excreted unchanged in urine.
Primarily fecal (84%) after biliary excretion; renal excretion accounts for <6% as unchanged drug and metabolites.
Category C
Category C
Antiarrhythmic
Antiarrhythmic